Chugai Pharmaceutical

AdipoSeeds, though a novel technology, creates platelets from mesenchymal stem cells without a complex and costly gene transfer. It aims to invent new blood supply system to solve the shortage of platelets in the world, and to create a future where a platelet-related treatment will be cheaply and safely provided.

Preferred Networks, Inc. is a Tokyo-based company founded in 2014 that specializes in software development services focused on real-time machine learning and deep learning technologies. The company aims to create practical applications for the Internet of Things, particularly in transportation systems, manufacturing, and bio-healthcare. Its services encompass data analytics, edge computing, distributed intelligence, and computer vision, catering to various sectors including retail, automotive, healthcare, advertising, life sciences, manufacturing, public safety, network security, and transportation. Preferred Networks also explores the integration of machine learning in areas such as personal robotics, plant optimization, materials discovery, and sports analytics. With a branch in Berkeley, California, the company is dedicated to advancing technologies that combine data from the physical and digital realms for applications like autonomous driving and medical diagnosis.

iPS PORTAL, Inc., founded in 2014 and based in Kyoto, Japan, specializes in the development of instruments for analyzing and measuring cells. The company focuses on contract testing of induced pluripotent stem (iPS) cells, aiming to promote the widespread adoption of iPS cell technology. iPS PORTAL provides research and development outsourcing services that support the practical application of iPS cell technology. Its offerings include assistance in research, contract testing, development, concept planning, and training programs in cell culture for researchers. By facilitating these services, iPS PORTAL enables healthcare companies to enhance research efforts and expedite the commercialization of drug discovery and regenerative medicine.

TWOCELLS Company Limited, established in 2003 and located in Hiroshima, Japan, specializes in the research, development, manufacturing, and sales of therapeutic genes, cells, drugs, diagnostic agents, chemical reagents, and medical materials. In addition to these core activities, the company also focuses on the development of medical appliances, instruments, and software systems related to regenerative medicine. Through its diverse offerings, TWOCELLS aims to contribute to advancements in healthcare and medical technology.

Gen-Probe Incorporated develops, manufactures, and markets nucleic acid probe-based products used for the clinical diagnosis of human diseases, and for screening donated human blood in North America and internationally. The company markets and sells its clinical diagnostic products in the United States directly and outside the United States primarily through distributors, as well as through its direct sales force, and the company also markets and sells its other products through collaborative partners. The company's blood screening products are marketed and distributed worldwide by Novartis. In addition, the company has agreements with Siemens (as assignee of Bayer Corporation), bioMérieux, Inc., or bioMérieux, and Fujirebio, Inc., through its subsidiary Rebio Gen, Inc., or Rebio Gen, to market products in various overseas markets. The company is developing NAT assays and instruments for the detection of harmful pathogens in the environment and biopharmaceutical and beverage manufacturing processes. The company has entered into collaboration agreements with GE Infrastructure Water and Process Technologies, or GEI, a unit of General Electric Company, and Millipore Corporation, or Millipore, under which the company would be primarily responsible for developing and manufacturing assays for exclusive use or sale by its collaborative partners in specified fields with in the industrial testing market. Products The company has applied its core technologies to develop multiple product lines, all of which utilize its expertise in NAT probes, sample collection and processing. The company categorizes its products into clinical diagnostic products and blood screening products. Clinical Diagnostic Products Within its clinical diagnostic product group, the company has developed products for the detection of non-viral and viral microorganisms and for the detection of markers for cancer. Clinical Diagnostic Products for the Detection of Non-Viral Microorganisms The company has developed FDA-approved amplified and non-amplified NAT assays that detect non-viral micro-organisms primarily for use in clinical diagnostics. The company's principal products for the detection of non-viral microorganisms include its non-amplified AccuProbe and PACE family of products and its amplified Mycobacterium Tuberculosis Direct Test and amplified APTIMA products. AccuProbe Products: The company's AccuProbe Culture Identification products are tools for the identification of mycobacterial, fungal and bacterial pathogens, with sensitivities and specificities approaching 100% in most cases. These products allow for the detection of target organisms from primary cultures, eliminating the additional labor of purifying secondary cultures. All AccuProbe Culture Identification assays are based on its HPA technology. As part of its AccuProbe Culture Identification product line, the company also has developed a procedure to detect GBS from broth culture. Group A Streptococcus Direct: The Group A Streptococcus Direct Test, or GASDirect assay, is a NAT assay for the direct detection of Streptococcus pyogenes in one hour from a throat swab. PACE Product Family: The company's PACE 2C offers the testing for both chlamydia infections and gonorrhea from a single patient specimen.